Replies to post #77564 on Avid Bioservices Inc (CDMO)

[swg_tdr]

thanks, RR and Thurly for recap -- QUESTION

assuming that the AACR presentation on Liver IST in a couple of weeks has some hard figures, and traders and speculators pick up on it re "non dilutive Asian partner financing"

do you think that the algorithm trader(s) of the last few months can hold up a SP advance? we have been in an iron grip with 0.75cents to 0.01cents bid/ask spread, running it any way he likes?

IMO, whoever has been vaccuming up those cheap shares is not quite finished doing so.

greatly looking forward to your view re this highly destructive market play -- quite different times now from the early dandreon SP surpression that used naked shorting, but seems weird to have machine trading in a small stock like ours.

thanks,
NHwild

[freethemice]

Sorafenib in Asian HCC patients. I updated the data for sorafenib with two trials done in Asia.
For comparisons I also added the percentage of the patients with HCV or HBV infection.
The Asian patients are almost all infected with HBV. This does make a difference in their survival.
From the paper, Cantarini et al, American Journal of Gastroenterology, 101, 91-98 (2006),
Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma.
"In the whole population, patients with hepatitis B tended to have a poor prognosis than those with
hepatitis C (p = 0.160), and this difference became statistically significant among the patients with
an advanced hepatocellular carcinoma (p = 0.025)."
This probably explains the differences between the non-Asian and the Asian trials below.
If bavi + sorafenib shows an increase in survival then I would think the very large Asian market would be in play.